Anand A, Acharya S
J Clin Exp Hepatol. 2024; 14(4):101361.
PMID: 38444405
PMC: 10910335.
DOI: 10.1016/j.jceh.2024.101361.
Giuli L, Maestri M, Santopaolo F, Pompili M, Ponziani F
Metabolites. 2023; 13(6).
PMID: 37367929
PMC: 10305328.
DOI: 10.3390/metabo13060772.
Rashidi-Alavijeh J, Nuruzade N, Frey A, Huessler E, Horster A, Zeller A
JHEP Rep. 2023; 5(4):100688.
PMID: 36926273
PMC: 10011825.
DOI: 10.1016/j.jhepr.2023.100688.
Caraceni P, Vargas V, Sola E, Alessandria C, de Wit K, Trebicka J
Hepatology. 2021; 74(3):1660-1673.
PMID: 33421158
PMC: 8518409.
DOI: 10.1002/hep.31708.
Bajaj J, OLeary J, Tandon P, Wong F, Kamath P, Biggins S
Aliment Pharmacol Ther. 2019; 49(12):1518-1527.
PMID: 31032966
PMC: 6538445.
DOI: 10.1111/apt.15265.
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho M, Kim S, Suk K, Kim B
J Microbiol. 2018; 56(12):855-867.
PMID: 30377993
DOI: 10.1007/s12275-018-8346-2.
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
Neff G, Zachry III W
Pharmacoeconomics. 2018; 36(7):809-822.
PMID: 29651649
PMC: 5999147.
DOI: 10.1007/s40273-018-0641-6.
The Pharmabiotic Approach to Treat Hyperammonemia.
Liu J, Lkhagva E, Chung H, Kim H, Hong S
Nutrients. 2018; 10(2).
PMID: 29382084
PMC: 5852716.
DOI: 10.3390/nu10020140.
Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review.
Sidhu G, Go A, Attar B, Mutneja H, Arora S, Patel S
BMJ Open Gastroenterol. 2017; 4(1):e000154.
PMID: 28944070
PMC: 5606119.
DOI: 10.1136/bmjgast-2017-000154.
Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability.
Beig A, Fine-Shamir N, Lindley D, Miller J, Dahan A
AAPS J. 2017; 19(3):806-813.
PMID: 28204967
DOI: 10.1208/s12248-017-0052-1.
Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.
Kang D, Kakiyama G, Betrapally N, Herzog J, Nittono H, Hylemon P
Clin Transl Gastroenterol. 2016; 7(8):e187.
PMID: 27560928
PMC: 5543406.
DOI: 10.1038/ctg.2016.44.
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani F, Gerardi V, Pecere S, DAversa F, Lopetuso L, Zocco M
World J Gastroenterol. 2015; 21(43):12322-33.
PMID: 26604640
PMC: 4649116.
DOI: 10.3748/wjg.v21.i43.12322.
Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.
Patidar K, Bajaj J
Clin Gastroenterol Hepatol. 2015; 13(12):2048-61.
PMID: 26164219
PMC: 4618040.
DOI: 10.1016/j.cgh.2015.06.039.
When to use antibiotics in the cirrhotic patient? The evidence base.
Anastasiou J, Williams R
Ann Gastroenterol. 2014; 26(2):128-131.
PMID: 24714766
PMC: 3959942.
Rifaximin in the treatment of hepatic encephalopathy.
Iadevaia M, Del Prete A, Cesaro C, Gaeta L, Zulli C, Loguercio C
Hepat Med. 2013; 3:109-17.
PMID: 24367227
PMC: 3846583.
DOI: 10.2147/HMER.S11988.
Antibiotics for the treatment of hepatic encephalopathy.
Patidar K, Bajaj J
Metab Brain Dis. 2013; 28(2):307-12.
PMID: 23389621
PMC: 3654040.
DOI: 10.1007/s11011-013-9383-5.
Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.
Romeiro F, Yamashiro F, Americo M, Cora L, Silva G, de Arruda Miranda J
BMC Gastroenterol. 2013; 13:13.
PMID: 23324408
PMC: 3551652.
DOI: 10.1186/1471-230X-13-13.
Rifaximin therapy and hepatic encephalopathy: Pros and cons.
Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo S, Riggio O
World J Gastrointest Pharmacol Ther. 2012; 3(4):62-7.
PMID: 22966484
PMC: 3437447.
DOI: 10.4292/wjgpt.v3.i4.62.
Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.
Zhu Q, Zou L, Jagavelu K, Simonetto D, Huebert R, Jiang Z
J Hepatol. 2011; 56(4):893-9.
PMID: 22173161
PMC: 3307873.
DOI: 10.1016/j.jhep.2011.11.013.
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
Bajaj J, Pinkerton S, Sanyal A, Heuman D
Hepatology. 2011; 55(4):1164-71.
PMID: 22135042
PMC: 3319334.
DOI: 10.1002/hep.25507.
